Trial reportHeart (British Cardiac Society)2006
Economic evaluation of the impact of nicorandil in angina (IONA) trial.
Trial report in Heart (British Cardiac Society), 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 25 citations in OpenAlex.
- Nicorandil-induced Isolated Abducens Nerve Palsy.Internal medicine (Tokyo, Japan) · 2025Article
- The Role of Nicorandil in the Management of Chronic Coronary Syndromes in the Gulf Region.Advances in therapy · 2021Review
- Nicorandil effects on platelet function, Hs-CRP, MMP-9 and myocardial antioxidation in patients with unstable angina.Experimental and therapeutic medicine · 2019Article
- Time for cooperation in health economics among the modelling community.PharmacoEconomics · 2010Article
- Medical therapy versus percutaneous coronary interventions for patients with stable and unstable coronary artery disease.Current atherosclerosis reports · 2008Review
- Utility of ranolazine in chronic stable angina patients.Vascular health and risk management · 2008Review
- Nicorandil: A drug with ongoing benefits and different mechanisms in various diseased conditions.Indian journal of pharmacologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo estimate the net cost of adding nicorandil to usual treatment for patients with angina and to compare this with indicators of health benefit.
designCost effectiveness analysis.
settingBased on results of the IONA (impact of nicorandil on angina) trial. PATIENTS: Patients with angina fulfilling the entry criteria for the IONA trial.
interventionsIn one arm of the trial nicorandil was added to existing antianginal treatment and compared with existing treatment alone.
main outcome measuresCosts were for use of hospital resources (for cardiovascular, cerebrovascular, and gastrointestinal reasons), nicorandil, and care after hospital discharge. Benefits were assessed in three ways: (1) IONA trial primary outcome (coronary heart disease (CHD) death, non-fatal myocardial infarction, or hospital admission for cardiac chest pain); (2) acute coronary syndrome (CHD death, non-fatal myocardial infarction, or unstable angina); and (3) event-free survivors at the end of the trial.
resultsThe net cost for each additional IONA trial end point averted was -5 pounds sterling (-7 euros). The net cost for each case of acute coronary syndrome averted was -8 pounds sterling (-12 euros). The net cost for each event-free survivor was -5 pounds sterling (-7 euros). These figures are based on gastrointestinal events that were judged definitely or probably related to nicorandil. When all gastrointestinal events were included these three ratios rose to 567 pounds sterling (835 euros), 886 pounds sterling (1305 euros), and 516 pounds sterling (760 euros), respectively.
conclusionsA substantial amount of the additional cost of nicorandil is offset by reduced use of hospital services. The limited comparisons possible with other CHD interventions suggest that nicorandil compares favourably.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.